Idiotype immunization combined with granulocyte-macrophage colony- stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses

Blood

Volumn 91, Issue 7, 1998, Pages 2459-2466

  Österborg, Anders ^a   Yi, Qing ^b   Henriksson, Lotta ^b   Fagerberg, Jan ^b   Bergenbrant, Susanne ^b   Jeddi Tehrani, Mahmood ^b   Rudén, Ulla ^b   Lefvert, Ann Kari ^b   Holm, Göran ^b   Mellstedt, Håkan ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MYELOMA; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0032055911     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.7.2459.2459_2459_2466     Document Type: Article

References (56)

1. Mellstedt H, Holm G, Björkholm M: Multiple myeloma, Waldenström's macroglobulinemia and benign monoclonal gammopathy: Characteristics of the B-cell clone, immunoregulatory cell populations and clinical implications. Adv Cancer Res 41:257, 1984
2. Bogen B: Processing and presentation of immunoglobulin idiotypes to T cells. Immunologist 1:121, 1993
3. Weiss S, Bogen B: B-lymphoma cells process and present their endogenous immunoglobulin to major histocompatibility complex-restricted T cells. Proc Natl Acad Sci USA 86:282, 1989
4. Lynch RG, Graff RJ, Sirisinha S, Simms ES, Eisen HN: Myeloma proteins as tumor-specific transplantation antigens. Proc Natl Acad Sci USA 69:1540, 1972
5. Hoover RG, Kornbluth J: Immunoregulation of murine and human myeloma. Hematol Oncol Clin North Am 6:407, 1992
6. Yi Q, Österborg A: Idiotype-specific T cells in multiple myeloma: Targets for an immunotherapeutic intervention? Med Oncol 13:1, 1996
7. Daley MJ, Gebel HM, Lynch RG: Idiotype specific transplantation resistance to MOPC-315: Abrogation by post-immunization thymectomy. J Immunol 120:1620, 1978
8. George AT, Folkard SG, Hamblin TJ, Stevenson FK: Idiotypic vaccination as a treatment for a B-cell lymphoma. J Immunol 141:2168, 1988
9. Rock KL: A new foreign policy: MHC class I molecules monitor the outside world. Immunol Today 17:131, 1996
10. Fischer HG, Frosch S, Reske K, Reske-Kunz AB: Granulocyte-macrophage colony-stimulating factor activates macrophages derived from bone marrow cultures to synthesis of MHC class II molecules and to augmented antigen presentation function. J Immunol 141:3882, 1988
11. Sallusto F, Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J Exp Med 179:1109, 1994
12. Tarr PE, Lin R, Mueller EA, Kovarik JM, Guillaume M, Jones TC: Evaluation of tolerability and antibody response after recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and a single dose of recombinant hepatitis B vaccine. Vaccine 14:1199, 1996
13. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539, 1993
14. Durie BGM, Salmon SE: A clinical staging system for multiple myeloma. Cancer 36:842, 1975
15. Österborg A, Björkholm M, Björeman M, Brenning G, Carlson K, Celsing F, Gahrton G, Grimfors G, Gyllenhammar H, Hast R, Johansson B, Juliusson G, Järnmark M, Kimby E, Lerner R, Linder O, Merk K, Nilsson B, Ohrling M, Paul C, Simonsson B, Smedmyr B, Svedmyr E, Stalfelt A-M, Strander H, Udén A-M, Ösby E, Mellstedt H: Natural interferon-α in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: A randomized study from the Myeloma Group of Central Sweden. Blood 81:1428, 1993
16. Bergenbrant S, Yi Q, Ösby E, Österborg A, Östman, R, Björkholm M, Holm G, Lefvert A-K: Anti-idiotypic B lymphocytes in patients with monoclonal gammopathies. Scand J Immunol 40:216, 1994
17. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156, 1987
18. + peripheral T cells. Human Immunol 40:93, 1994
19. Deane M, Norton J: Detection of immunoglobulin gene rearrangement in B lymphoid malignancies by polymerase chain reaction gene amplification. Br J Haematol 74:251, 1990
20. Pannetier C, Cochet M, Darche S, Casrouge A, Zöller M, Kourilsky P: The size of the CDR3 hypervariable regions of the murine T-cell receptor beta chains vary as a function of the recombined germ-line segments. Proc Natl Acad Sci USA 90:4319, 1993
21. Fields GB, Noble RL: Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res 35:161, 1990
22. Bergenbrant S, Yi Q, Österborg A, Björkholm M, Ösby E, Mellstedt H, Lefvert A-K, Holm G: Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients. Br J Haematol 92:840, 1996
23. Österborg A, Yi Q, Bergenbrant S, Holm G, Lefvert A-K, Mellstedt H: Idiotype-specific T cells in multiple myeloma stage I: An evaluation by four different functional tests. Br J Haematol 89:110, 1995
24. Fagerberg J, Steinitz M, Wigzell H, Askelöf P, Mellstedt H: Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients. Proc Natl Acad Sci USA 92:4773, 1995
25. Yi Q, Bergenbrant S, Österborg A, Ösby E, Östman R, Björkholm M, Holm G, Lefvert A-K: T-cell stimulation induced by idiotypes on monoclonal immunoglobulins in patients with monoclonal gammopathies. Scand J Immunol 38:529, 1993
26. Yi Q, Österborg A, Bergenbrant S, Mellstedt H, Holm G, Lefvert A-K: Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood 86:3043, 1995
27. Yi Q, Holm G, Lefvert A-K: Idiotype-induced T cell stimulation required antigen presentation in association with HLA-DR molecules. Clin Exp Immunol 104:359, 1996
28. Kwak LH, Taub DD, Duffey PL, Bensinger WI, Bryant EM, Reynolds CW, Longo DL: Transfer of myeloma idiotype-specific immunity from an actively immunized marrow donor. Lancet 345:1016, 1995
29. Lynch RG: Immunoglobulin-specific suppressor T cells. Adv Immunol 40:135, 1987
30. Sirisinha S, Eisen HN: Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins. Proc Nat Acad Sci USA 68:3130, 1971
31. Chen Y, Yakulis V, Heller P: Passive immunity to murine plasmacytoma by rabbit anti-idiotypic antibody to myeloma protein. Proc Soc Exp Biol Med 151:121, 1976
32. Lauritzsen GG, Weiss S, Bogen, B: Anti-tumor activity of idiotype-specific, MHC-restricted Th1 and Th2 clones in vitro and in vivo. Scand J Immunol 37:77, 1993
33. + T-cells in eradication of a large subcutaneous MOPC-315 tumor following low-dose melphalan therapy. Cancer Res 50:7641, 1990
34. Nelson EL, Li X, Hsu FJ, Kwak LW, Levy R, Clayberger C, Krensky AM: Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma. Blood 88:580, 1996
35. Mosman TR, Sad S: The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 17:138, 1996
36. Kabilan L, Troye-Blomberg M, Perlmann H, Andersson G, Högh B, Petersen E, Björkman A, Perlmann P: T-cell epitopes in Pf155/RESA, a major candidate for a Plasmodium falciparum malaria vaccine. Proc Natl Acad Sci USA 85:5659, 1988
37. Surcel HM, Troye-Blomberg M, Paulie S, Andersson G, Moreno C, Pasvol G, Ivanyi J: Th1/Th2 profiles in tuberculosis, based on the proliferation and cytokine response of blood lymphocytes to mycobacterial antigens. Immunology 81:171, 1994
38. Levitsky HI, Montgomery J, Ahmadzadeh M, Staveley-O'Carroll K, Guarnieri F, Longo DL, Kwak LW: Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J Immunol 156:3858, 1996
39. Tao M-H, Levy R: Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362:755, 1993
40. Disis ML, Bernhard H, Shiota FM, Hand SL, Gralow JR, Huseby ES, Gillis S, Cheever MA: Granulocyte-macrophage colony-stimulating factor: An effective adjuvant for protein and peptide-based vaccines. Blood 88:202, 1996
41. Kwak LW, Young HA, Pennington RW, Weeks SD: Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci USA 93:972, 1996
42. Fagerberg J, Samanci A, Yi Q, Strigård K, Rudén U, Wahren B, Mellstedt H: Recombinant carcinoembryonic antigen and granulocyte-macrophage colony-stimulating factor for active immunization of colorectal carcinoma patients. J Immunother 19:461, 1996 (abstr)
43. Tan KC, Hosoi J, Grabbe S, Asahina A, Granstein RD: Epidermal cell presentation of tumor-associated antigens for induction of tolerance. J Immunol 153:760, 1994
44. Grabbe S, Beissert S, Schwartz T, Granstein RD: Dendritic cells as initiators of tumor immune response: A possible strategy for tumor immunotherapy? Immunol Today 16:117, 1995
45. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52, 1996
46. + T cells. J Clin Invest 94:797, 1994
47. + helper T cells. J Exp Med 171:1315, 1990
48. + T cells in vivo. Proc Natl Acad Sci USA 91:3077, 1994
49. Bevan MJ: Class discrimination in the world of immunology. Nature 325:192, 1987
50. Falo LD, Kovacsovics-Bankowski M, Thompson K, Rock KL: Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nat Med 1:649, 1995
51. Paglia P, Chiodoni C, Rodolfo M, Colombo MP: Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 183:317, 1996
52. 2 fragments of the idiotypic immunoglobulin in patients with monoclonal gammopathy. Cancer Immunol Immunother 34:157, 1991
53. + subsets. Br J Haematol 96:338, 1997
54. Zhang X-G, Bataille R, Jourdan M, Saeland S, Banchereau J, Mannoni P, Klein B: Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells. Blood 76:2599, 1990
55. Celsing F, Hast R, Stenke L, Hansson H, Pisa P: Extramedullary progression of multiple myeloma following GM-CSF treatment -grounds for caution? Eur J Haematol 49:108, 1992
56. Hawkins RE, Zhu D, Ovecka M, Winter G, Hamblin TJ, Long A, Stevenson FK: Idiotypic vaccination against human B-cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single-chain fv personal vaccines. Blood 83:3279, 1994